



United States of America
FEDERAL TRADE COMMISSION
Washington, D.C. 20580

Office of the Secretary

August 21, 2014

Mark Mead
Natural Health Foundation
P.O. Box 17012
Chapel Hill, NC 27705

Re: *In the Matter of i-Health, Inc. and Martek Biosciences Corp.*
FTC File No. 122-3067, Docket No. C-4486

Dear Mr. Mead:

Thank you for your comment regarding the above-referenced matter. Your letter was placed on the public record pursuant to Section 2.34 of the Commission's Rules of Practice, 16 C.F.R. § 2.34, and was given serious consideration by the Commission.

In your comment, you argue that the Commission should not challenge dietary supplement advertising claims that it has reason to believe are false or unsubstantiated when the product is safe and those claims purportedly derive from a well-designed, randomized controlled clinical trial, because the effect may be to deny consumers useful information. As indicated in the individual Commissioners' statements, the Commission considered this concern in determining whether to issue the proposed complaint and consent order in this matter. Similar concerns also were addressed in the individual Commissioners' statements in *foru™ Int'l Corp.*, FTC File No. 112-3095 (Jan. 7, 2014), available at <http://www.ftc.gov/enforcement/cases-proceedings/112-3095/forutm-international-corporation-matter>. Therefore, the Commission has determined that the public interest is best served by issuing the Decision and Order in final form without modification. A copy of the final Decision and Order, and other relevant materials, are available from the Commission's website at <http://www.ftc.gov>.

It helps the Commission's analysis to hear from a variety of sources in its work, and we thank you again for your letter.

By direction of the Commission, Commissioner Ohlhausen dissenting and Commissioner McSweeney not participating.

Donald S. Clark
Secretary